Q1 Earnings Estimate for biote Issued By Roth Capital

biote Corp. (NASDAQ:BTMD - Free Report) - Research analysts at Roth Capital issued their Q1 2026 earnings per share (EPS) estimates for biote in a research note issued on Thursday, May 8th. Roth Capital analyst G. Kelly expects that the company will post earnings of $0.15 per share for the quarter. The consensus estimate for biote's current full-year earnings is $0.75 per share. Roth Capital also issued estimates for biote's Q2 2026 earnings at $0.15 EPS, Q3 2026 earnings at $0.20 EPS and Q4 2026 earnings at $0.21 EPS.

biote (NASDAQ:BTMD - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.08 EPS for the quarter, topping the consensus estimate of $0.06 by $0.02. The company had revenue of $48.99 million for the quarter, compared to analyst estimates of $47.25 million. biote had a negative return on equity of 32.41% and a net margin of 5.20%.

Separately, Craig Hallum dropped their target price on biote from $12.00 to $8.00 and set a "buy" rating on the stock in a report on Thursday, March 13th.

biote Stock Up 6.7%

BTMD opened at $3.99 on Monday. The firm has a market cap of $218.29 million, a price-to-earnings ratio of 15.35 and a beta of 1.17. biote has a 52 week low of $3.04 and a 52 week high of $8.44. The business's 50 day moving average is $3.61 and its two-hundred day moving average is $4.93.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Public Employees Retirement System of Ohio acquired a new position in biote during the fourth quarter worth $69,000. Squarepoint Ops LLC acquired a new position in biote during the fourth quarter worth $115,000. Millennium Management LLC acquired a new position in biote during the fourth quarter worth $414,000. Lazard Asset Management LLC acquired a new position in biote during the fourth quarter worth $139,000. Finally, Deutsche Bank AG grew its holdings in biote by 4,987.5% during the fourth quarter. Deutsche Bank AG now owns 31,441 shares of the company's stock worth $194,000 after acquiring an additional 30,823 shares during the period. Institutional investors and hedge funds own 21.68% of the company's stock.

Insider Activity

In related news, major shareholder Guines Llc bought 106,000 shares of the company's stock in a transaction dated Monday, March 31st. The shares were acquired at an average price of $3.32 per share, with a total value of $351,920.00. Following the completion of the acquisition, the insider now owns 4,033,547 shares in the company, valued at approximately $13,391,376.04. This trade represents a 2.70% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Stephen Mark Cone bought 38,104 shares of the company's stock in a transaction dated Monday, March 17th. The stock was bought at an average cost of $3.88 per share, for a total transaction of $147,843.52. Following the acquisition, the director now owns 160,829 shares of the company's stock, valued at approximately $624,016.52. This trade represents a 31.05% increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders have purchased 1,412,080 shares of company stock valued at $4,598,190. Company insiders own 24.00% of the company's stock.

About biote

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.